WHAT IS CLAIMED IS:

1. An isolated or recombinant polypeptide, wherein the polypeptide is comprised of a ApoA-I Binding Protein (AIBP) amino acid sequence and an amino acid sequence N-terminal to the AIBP amino acid sequence,

wherein the amino acid sequence N-terminal to the AIBP amino acid sequence is MSPIDPMGHHHHHHGRRRASVAAGILVPRGSPGLDGICSR (SEQ ID NO:2),

wherein the amino acid sequence N-terminal to the AIBP amino acid sequence is capable of inducing unfolding, exposing or otherwise making accessible a cryptic domain in the AIBP amino acid sequence for binding of the polypeptide to TLR4 under relevant physiological conditions,

wherein optionally "relevant physiological conditions" refer to those conditions to be experienced by the polypeptide compound *in vivo* upon providing it to a subject in need thereof by administration.

2. The isolated or recombinant polypeptide of claim 1, wherein the AIBP sequence is

MSPIDPMGHHHHHHGRRRASVAAGILVPRGSPGLDGICSRQTIACRSGPTWW GPQRLNSGGRWDSEVMASTVVKYLSQEEAQAVDQELFNEYQFSVDQLMELAGLSCA TAIAKAYPPTSMSRSPPTVLVICGPGNNGGDGLVCARHLKLFGYEPTIYYPKRPNKPLF TALVTQCQKMDIPFLGEMPAEPMTIDELYELVVDAIFGFSFKGDVREPFHSILSVLKGL TVPIASIDIPSGWDVEKGNAGGIQPDLLISLTAPKKSATQFTGRYHYLGGRFVPPALEK KYQLNLPPYPDTECVYRLQ.

3. The isolated or recombinant polypeptide compound of claim 1, wherein the AIBP amino acid sequence is that of a mammalian AIBP amino acid sequence.

4. The isolated or recombinant polypeptide compound of claim 3, wherein the mammalian AIBP amino acid sequence is that of a human AIBP amino acid sequence.

5. The isolated or recombinant polypeptide compound of claim 4, wherein the human AIBP amino acid sequence is the human AIBP amino acid sequence of 25-288 amino acid residues with NCBI Reference Sequence: NP_658985.2 having deletion of amino acids 1-24 from said AIBP amino acid sequence.

6. A pharmaceutical composition comprised of a polypeptide compound of any

one of claims 1 to 5 and at least one excipient suitable for parenteral administration.

7. The pharmaceutical composition of claim 6, wherein parenteral administration is by intrathecal injection or intrathecal implant.

8. A nucleic acid compound, wherein the nucleic acid compound is comprised of a nucleic acid sequence that encodes for the polypeptide compound of any one of claims 1 to 5.

9. An expression vector comprised of a nucleic acid sequence that encodes for the polypeptide compound of any one of claims 1 to 5.

10. A kit comprising a recombinant or isolated polypeptide of any one of claims 1 to 5, or pharmaceutical composition of claim 6 or 7.

11. A recombinant or isolated polypeptide of any one of claims 1 to 5, or a pharmaceutical composition of claim 6 or 7 for use as a medicament.

12. Use of a recombinant or isolated polypeptide of any of claims 1 to 5 or a pharmaceutical composition of claim 6 or 7, in the manufacture of a medicament for treating, ameliorating or preventing a disease or condition selected from the group consisting of:

- neuropathic pain,
- inflammation-induced neuropathic pain,
- nerve or CNS inflammation,
- allodynia,
- a post nerve or tissue injury pain or neuropathic pain,
- post-surgical pain or neuropathic pain,
- chemotherapeutic-induced peripheral neuropathy (CIPN) (for example, a cisplatin-induced CIPN or allodynia),
- a neurodegenerative disease or condition,
- a primary headache,
- hyperalgesia,
- glaucoma or other inflammatory diseases of the eye,

- lung inflammation and asthma,

- acute respiratory distress syndrome (ARDS),

- sepsis,

- viral infection,

- vascular inflammation, atherosclerosis and cardiovascular disease, and combinations thereof.

13. The use of a recombinant or isolated polypeptide or pharmaceutical composition of claim 12, wherein

- the inflammation-induced neuropathic pain comprises a Toll-like receptor 4 (TLR4)-mediated inflammation-induced neuropathic pain,

- the nerve or CNS inflammation comprises a TLR4-mediated nerve or CNS inflammation,

- the allodynia comprises a TLR4-mediated allodynia,

- the post nerve or tissue injury pain or neuropathic pain is generated or caused by, or is a sequelae to, trauma, chemotherapy, arthritis, diabetes, or viral infection,

- the neurodegenerative disease or condition is a chronic or progressive neurodegenerative disease or condition, optionally Alzheimer's disease, chronic traumatic encephalopathy (CTE) or a related tauopathy, traumatic brain injury (TBI), post-traumatic stress disorder, traumatic war neurosis, or post-traumatic stress syndrome (PTSS),

- the primary headache is a migraine or a cluster headache,

- the viral infection is caused by an influenza virus (optionally an influenza A, B or C), a coronavirus (optionally the coronavirus is COVID-19), a human immunodeficiency virus (HIV), a hepatitis virus, a respiratory syncytial virus (RSV), a Paramyxovirus, a Herpes simplex virus (HSV), a Cytomegalovirus (CMV), an Epstein-Barr virus (EBV), a Dengue virus, a Zika virus, or a chikungunya virus, or comorbidities thereof.